A5024607107- Multiple Myeloma Research and Treatments
- Peptidase Inhibition and Analysis
- Immunotherapy and Immune Responses
- Protein Degradation and Inhibitors
- Cancer Mechanisms and Therapy
- Lymphoma Diagnosis and Treatment
- Chemokine receptors and signaling
- Viral-associated cancers and disorders
- Cancer therapeutics and mechanisms
- Cancer Treatment and Pharmacology
- Chronic Lymphocytic Leukemia Research
- Amyloidosis: Diagnosis, Treatment, Outcomes
- Renal Transplantation Outcomes and Treatments
- Hematological disorders and diagnostics
- Platelet Disorders and Treatments
- Polyomavirus and related diseases
- Kawasaki Disease and Coronary Complications
- Eosinophilic Disorders and Syndromes
- Neurological Complications and Syndromes
- vaccines and immunoinformatics approaches
- Biological Research and Disease Studies
- Immunodeficiency and Autoimmune Disorders
- Blood Coagulation and Thrombosis Mechanisms
- Vascular Tumors and Angiosarcomas
- Hematopoietic Stem Cell Transplantation
Sichuan University
2016-2025
West China Hospital of Sichuan University
2016-2025
Peking Union Medical College Hospital
2015
Chinese Academy of Medical Sciences & Peking Union Medical College
2015
Castleman disease (CD) is a group of rare and heterogenous lymphoproliferative disorders including unicentric CD (UCD), human herpesvirus-8(HHV-8)-associated multicentric (HHV8-MCD), HHV-8-negative/idiopathic (iMCD). Knowledge mainly comes from case series or retrospective studies, but the inclusion criteria these studies vary because Disease Collaborative Network (CDCN) diagnostic for iMCD UCD were not available until 2017 2020, respectively. Further, guidelines have been systematically evaluated.
Abstract Background Chromosomal 1q gains and amplifications (+1q21) are frequently observed in patients with newly diagnosed multiple myeloma (NDMM). However, the interpretation of high‐risk (HR) prognostic implications stemming from 1q21 abnormalities remain challenging to implement effectively. Methods In a comprehensive analysis 367 consecutive symptomatic MM, we assessed significance +1q21 using FISH threshold 7.4%. The patient cohort was randomly divided into training set (66.5%, n =...
Abstract Objective TQB3602 is a novel orally bioavailable proteasome inhibitor. This study the first‐in‐human phase I clinical trial to evaluate safety, tolerability, pharmacokinetics, and preliminary efficacy of in relapsed/refractory multiple myeloma (RRMM). Methods multicenter consisting 3+3 dose‐escalation dose expansion phase. Patients with MM who have received ≥2 prior antimyeloma therapies were enrolled. administered at 0.5~7mg on days 1, 8, 15 28‐day cycle. Results Twenty‐five RRMM...
Background: For multiple myeloma (MM), the proportions of patients reaching subsequent line therapy (LOT) decline gradually and real-world data describing attrition rates LOT in Chinese MM were limited. Herein, we investigated by LOTs their relevant risk factors China. Methods: who had been hospitalized received at least one from January 2008 to August 2019 West China Hospital Sichuan University retrospectively recruited. Demographic clinical characteristic obtained “HemaTank” Multiple...
Summary Molecular and clinical stratification of patients with angioimmunoblastic T‐cell lymphoma (AITL) is unsatisfactory, which hinders the development personalized therapies. This study aimed to identify molecular biomarkers for AITL based on peripheral cell‐free DNA (cfDNA) that could be used predict prognosis guide treatment non‐invasively. A customized panel containing 46 genes was pretreatment cfDNA paired tumour tissues in 64 Chinese from three centres, gene mutations tissue were...
Multiple myeloma (MM) is a heterogeneous disease that remains incurable with significant interpatient variability in outcomes.Regulatory B cells (Bregs) were observed to be involved into specific defects MM.Here, we provide our risk-adapted approach newly diagnosed MM (NDMM), combining the fundamental dysfunction of Bregs.We reported one hundred consecutive patients NDMM from South-Western China, primarily treated bortezomib plus dexamethasone or without 3 rd agent, enrolled 2017.Bone marrow...
Abstract Objective Despite the availability of new agents, elderly patients with multiple myeloma (MM) usually present poor outcomes due to heterogeneity disease conditions, especially immune deficiency. Regulatory B cells (Bregs) can be involved in defects by exerting regulatory functions MM. In order provide more evidence‐based practice for MM, study established and assessed a stratified therapeutic model studies on Bregs Chinese Elderly Multiple Myeloma 2021 (CEMM2021). Methods this...
To assess patients with multiple myeloma (MM), the whole-body positron-emission tomography/computed tomography (PET/CT) occupies a pivotal position for diagnostic stratification, response evaluation, and survival prediction, while important limitations are recognized as incapable of representing tumor microenvironment. Regulatory B cells (Bregs) have been reported to an inhibitory immune function, contributing bone marrow (BM)-immunosuppressive microenvironment MM. Therefore, investigate...
Background Chidamide is subtype-selective histone deacetylase (HDAC) inhibitor that showed promising result in clinical trials to improve prognosis of angioimmunoblastic T-cell lymphoma (AITL) patients. However, real world settings, contradictory reports existed as whether chidamide overall survival (OS). Therefore, we aimed develop an interpretable machine learning (Machine learning)–based model predict the 2-year AITL patients based on usage and baseline features. Methods A total 183 with...
<title>Abstract</title> Fc receptors (FcRs) polymorphisms may affect the affinity of rituximab for antibody-dependent cellular cytotoxicity (ADCC) effector cells. The C1qA polymorphism influence C1q levels, but their significance in treatment response and survival is unknown. This study evaluated role FCGR3A, C1qA, HLA-G outcomes patients with diffuse large B cell lymphoma (DLBCL) treated chemotherapy. Genomic DNA was isolated from peripheral blood 314 newly diagnosed DLBCL. association...